Modality
Multispecific
MOA
STINGag
Target
FLT3
Pathway
STING
GA
Development Pipeline
Preclinical
~Mar 2018
→ ~Jun 2019
Phase 1
~Sep 2019
→ ~Dec 2020
Phase 2
~Mar 2021
→ ~Jun 2022
Phase 3
Sep 2022
→ Jan 2025
Phase 3Current
NCT04681968
959 pts·GA
2022-09→2025-01·Recruiting
959 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-01-161.2y agoPh3 Readout· GA
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025
P3
Recruit…
Catalysts
Ph3 Readout
2025-01-16 · 1.2y ago
GA
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04681968 | Phase 3 | GA | Recruiting | 959 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| RHH-5389 | Roche | Preclinical | RET | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 | |
| Miritinib | Neurocrine | Phase 3 | TIGIT |